Korsten, Peter

[["dc.bibliographiccitation.artnumber","2072143"],["dc.bibliographiccitation.journal","Human Vaccines & Immunotherapeutics"],["dc.contributor.author","Plüß, Marlene"],["dc.contributor.author","Piantoni, Silvia"],["dc.contributor.author","Tampe, Björn"],["dc.contributor.author","Kim, Alfred H. J."],["dc.contributor.author","Korsten, Peter"],["dc.date.accessioned","2022-06-01T09:39:18Z"],["dc.date.available","2022-06-01T09:39:18Z"],["dc.date.issued","2022"],["dc.description.abstract","In recent years, advances in the treatment and management of patients with systemic lupus erythematosus (SLE) have improved their life expectancy and quality of life. However, lupus nephritis (LN) still represents a major life-threatening complication of the disease. Belimumab (BEL), a fully human monoclonal IgG1λ antibody neutralizing soluble B cell activating factor, was approved more than ten years ago as add-on therapy in adults and pediatric patients with a highly active, autoantibody-positive disease despite standard of care (SoC). Recently, the superiority of the addition of BEL to SoC was also demonstrated in LN. In this review, we provide a comprehensive overview of the study landscape, available therapeutic options for SLE (focusing on BEL in renal and non-renal SLE), and new perspectives in the treatment field of this disease. A personalized treatment approach will likely become available with the advent of novel therapeutic agents for SLE and LN."],["dc.identifier.doi","10.1080/21645515.2022.2072143"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/108436"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-572"],["dc.relation.eissn","2164-554X"],["dc.relation.issn","2164-5515"],["dc.rights.uri","http://creativecommons.org/licenses/by-nc-nd/4.0/"],["dc.title","Belimumab for systemic lupus erythematosus – Focus on lupus nephritis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1057"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Zeitschrift für Rheumatologie"],["dc.bibliographiccitation.lastpage","1066"],["dc.bibliographiccitation.volume","79"],["dc.contributor.author","Juche, A."],["dc.contributor.author","Siegert, E."],["dc.contributor.author","Mueller-Ladner, U."],["dc.contributor.author","Riemekasten, G."],["dc.contributor.author","Günther, C."],["dc.contributor.author","Kötter, I."],["dc.contributor.author","Henes, J."],["dc.contributor.author","Blank, N."],["dc.contributor.author","Voll, R. E."],["dc.contributor.author","Ehrchen, J."],["dc.contributor.author","Schmalzing, M."],["dc.contributor.author","Susok, L."],["dc.contributor.author","Schmeiser, T."],["dc.contributor.author","Sunderkoetter, C."],["dc.contributor.author","Distler, J."],["dc.contributor.author","Worm, M."],["dc.contributor.author","Kreuter, A."],["dc.contributor.author","Horváth, O. N."],["dc.contributor.author","Schön, M. P."],["dc.contributor.author","Korsten, P."],["dc.contributor.author","Zeidler, G."],["dc.contributor.author","Pfeiffer, C."],["dc.contributor.author","Krieg, T."],["dc.contributor.author","Hunzelmann, N."],["dc.contributor.author","Moinzadeh, P."],["dc.date.accessioned","2020-12-10T14:10:25Z"],["dc.date.available","2020-12-10T14:10:25Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1007/s00393-019-00743-9"],["dc.identifier.eissn","1435-1250"],["dc.identifier.issn","0340-1855"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70754"],["dc.language.iso","de"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Versorgungsrealität der stationären vasoaktiven Therapie mit Prostazyklinderivaten bei Patienten mit akralen Durchblutungsstörungen bei systemischer Sklerose in Deutschland"],["dc.title.alternative","Reality of inpatient vasoactive treatment with prostacyclin derivatives in patients with acral circulation disorders due to systemic sclerosis in Germany"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","290"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Zeitschrift für Rheumatologie"],["dc.bibliographiccitation.lastpage","299"],["dc.bibliographiccitation.volume","74"],["dc.contributor.author","Korsten, Peter"],["dc.contributor.author","Mueller, Georg Anton"],["dc.date.accessioned","2018-11-07T09:57:36Z"],["dc.date.available","2018-11-07T09:57:36Z"],["dc.date.issued","2015"],["dc.description.abstract","Interstitial nephritis is responsible for about 12% of end-stage renal disease in Germany. It comprises an etiologically heterogenous group of inflammatory renal disorders which primarily affect the renal interstitium and tubuli. Drugs, predominantly antibiotics, nonsteroidal anti-inflammatory drugs and proton pump inhibitors are causative in the majority of cases. Rheumatic diseases frequently affect the kidneys, either the glomeruli or the interstitial tissues. Inflammatory interstitial processes can be accompanied by complex functional tubular disorders. This review gives an overview about clinical and laboratory findings of interstitial nephritis in the context of rheumatic diseases. Sarcoidosis, tubulointerstitial nephritis and uveitis (TINU) syndrome, primary Sjogren's syndrome, and IgG4-related disease often show an interstitial nephritis when the kidneys are affected. Other diseases, such as systemic lupus erythematosus, systemic sclerosis, drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, and granulomatosis with polyangiitis are more rarely associated with predominant interstitial nephritis. Glucocorticoids are the mainstay of therapy for most cases; in refractory cases or when side effects occur, second-line immunosuppressants such as mycophenolate mofetil, azathioprine and others, rarely biologics, can be used."],["dc.identifier.doi","10.1007/s00393-014-1482-0"],["dc.identifier.isi","000355606600004"],["dc.identifier.pmid","25962450"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37197"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","1435-1250"],["dc.relation.issn","0340-1855"],["dc.title","Interstitial nephritis in rheumatic diseases"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","annrheumdis-2020-218491"],["dc.bibliographiccitation.journal","Annals of the Rheumatic Diseases"],["dc.contributor.author","Hakroush, Samy"],["dc.contributor.author","Franz, Jonas"],["dc.contributor.author","Larsen, Jörg"],["dc.contributor.author","Korsten, Peter"],["dc.contributor.author","Winkler, Martin Sebastian"],["dc.contributor.author","Tampe, Björn"],["dc.date.accessioned","2021-06-01T10:47:36Z"],["dc.date.available","2021-06-01T10:47:36Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1136/annrheumdis-2020-218491"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85655"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.eissn","1468-2060"],["dc.relation.issn","0003-4967"],["dc.title","Repeated false-negative tests delayed diagnosis of COVID-19 in a case with granulomatosis with polyangiitis under maintenance therapy with rituximab and concomitant influenza pneumonia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1307"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Chest"],["dc.bibliographiccitation.lastpage","1308"],["dc.bibliographiccitation.volume","159"],["dc.contributor.author","Sweiss, Nadera J."],["dc.contributor.author","Korsten, Peter"],["dc.contributor.author","Baughman, Robert P."],["dc.contributor.author","Culver, Daniel A."],["dc.contributor.author","Judson, Marc A."],["dc.date.accessioned","2021-04-14T08:29:02Z"],["dc.date.available","2021-04-14T08:29:02Z"],["dc.date.issued","2021"],["dc.identifier.doi","10.1016/j.chest.2020.10.005"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/82773"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.issn","0012-3692"],["dc.title","Response"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Rheumatology"],["dc.bibliographiccitation.volume","56"],["dc.contributor.author","Korsten, Peter"],["dc.contributor.author","Bahlmann, Dirk"],["dc.contributor.author","Patschan, Susann Andrea"],["dc.date.accessioned","2018-11-07T10:22:05Z"],["dc.date.available","2018-11-07T10:22:05Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1093/rheumatology/kex007"],["dc.identifier.isi","000404610700010"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42214"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.issn","1462-0332"],["dc.relation.issn","1462-0324"],["dc.title","Rapid healing of peripheral ulcerative keratitis in rheumatoid arthritis with prednisone, methotrexate and adalimumab combination therapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2071"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Rheumatology"],["dc.bibliographiccitation.lastpage","2073"],["dc.bibliographiccitation.volume","58"],["dc.contributor.author","Korsten, Peter"],["dc.contributor.author","Seitz, Cornelia S"],["dc.contributor.author","Sahlmann, Carsten O"],["dc.contributor.author","Schmidt, Jens"],["dc.date.accessioned","2020-12-10T18:19:41Z"],["dc.date.available","2020-12-10T18:19:41Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1093/rheumatology/kez313"],["dc.identifier.eissn","1462-0332"],["dc.identifier.issn","1462-0324"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/75335"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Comment on: The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody–positive dermatomyositis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Rheumatology"],["dc.contributor.author","Piantoni, Silvia"],["dc.contributor.author","Korsten, Peter"],["dc.date.accessioned","2022-04-01T10:00:32Z"],["dc.date.available","2022-04-01T10:00:32Z"],["dc.date.issued","2022"],["dc.identifier.doi","10.1093/rheumatology/keac095"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/105451"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-530"],["dc.relation.eissn","1462-0332"],["dc.relation.issn","1462-0324"],["dc.title","Rituximab—a B cell targeted therapy in systemic lupus erythematosus: where do we stand?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","408"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Zeitschrift für Rheumatologie"],["dc.bibliographiccitation.lastpage","414"],["dc.bibliographiccitation.volume","76"],["dc.contributor.author","Korsten, P."],["dc.contributor.author","Chehab, G."],["dc.date.accessioned","2020-12-10T14:10:24Z"],["dc.date.available","2020-12-10T14:10:24Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1007/s00393-017-0313-5"],["dc.identifier.eissn","1435-1250"],["dc.identifier.issn","0340-1855"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70752"],["dc.language.iso","de"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Muskuloskelettale Manifestationen der Sarkoidose"],["dc.title.alternative","Musculoskeletal manifestations of sarcoidosis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Journal of Nephrology"],["dc.contributor.author","Hakroush, Samy"],["dc.contributor.author","Kluge, Ingmar Alexander"],["dc.contributor.author","Baier, Eva"],["dc.contributor.author","Korsten, Peter"],["dc.contributor.author","Tampe, Desiree"],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Tampe, Björn"],["dc.date.accessioned","2022-05-02T08:09:46Z"],["dc.date.available","2022-05-02T08:09:46Z"],["dc.date.issued","2022"],["dc.identifier.doi","10.1007/s40620-022-01320-1"],["dc.identifier.pii","1320"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/107458"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-561"],["dc.relation.eissn","1724-6059"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","pANCA autoantibody testing by indirect immunofluorescence indicates interstitial arteritis independent of MPO-ANCA immunoassays in ANCA-associated glomerulonephritis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]